glp-1 agonists and retained gastric contents at endoscopy Your patient took semaglutide this week. Cancel the EGD, proceed, or risk-stratify? The OCULUS randomized trial found clinically significant residual volume was higher when GLP-1/GIP were continued vs held for goal:weight-management FDA issued 25 warning Quantity:3 Month Supply (270 Count)

glp-1 agonists and retained gastric contents at endoscopy Your patient took semaglutide this week. Cancel the EGD, proceed, or risk-stratify? The OCULUS randomized trial found clinically significant residual volume was higher when GLP-1/GIP were continued vs held for goal:weight-management FDA issued 25 warning Quantity:3 Month Supply (270 Count)

FDA issued 25 warning letters to telehealth companies for false and misleading claims about compounded GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of

Shift toward non-daily dosing and non-injectable routes: weekly injectables, oral tablets and pipeline transdermal/patch approaches are reducing treatment burden

goal:weight-management

Quantity:3 Month Supply (270 Count)

Murphy, K., Travers, P., Walport, M., & Janeway, C